Source Pravda.Ru

Merck & Co ceases study of cholesterol drug

Merck & Co., Inc. (NYSE: MRK) has ceased trials of an experimental drug three weeks after U.S. regulators banned the sales of the drug.

One of the largest pharmaceutical companies in the world was working at cholesterol drug MK-0524A designed to reduce cholesterol levels. The drug combines the B vitamin niacin and a drug called laropiprant to limit the facial flushing caused by niacin.

The study of the drug used ultrasound imaging to monitor plaque buildup in arteries of people whose genes give them sky-high cholesterol levels.

The company suggests no link between FDA’s ban and termination of the study, in which half the patients got MK-0524A and half got dummy pills. The steering committee, which met on May 14, decided it was testing the wrong group of patients - people whose genes caused ultra-high cholesterol.

The committee comments the advice to stop the study by offering precedents, for example a controversial study called ENHANCE.

The co-author of this disaster is the Dutch government, which did not find either strength or desire to save the lives of its citizens who were flying on that plane. The Dutch authorities did not demand Ukraine to comply with international aviation regulations

Blame MH17 on Russia: International investigation turns into demonic circus

The co-author of this disaster is the Dutch government, which did not find either strength or desire to save the lives of its citizens who were flying on that plane. The Dutch authorities did not demand Ukraine to comply with international aviation regulations

Blame MH17 on Russia: International investigation turns into demonic circus

On the second day of the St. Petersburg International Economic Forum, a plenary meeting was held, in which Russian President Vladimir Putin, French President Emmanuel Macron, Japanese Prime Minister Shinzo Abe, Chinese Vice President Wang Qishan and IMF head Christine Lagarde took part

World leaders unite with Russia at St. Petersburg International Economic Forum